[Phosphodiesterase-4 inhibitors: roflumilast]

Area of Science:

• Pharmacology
• Pulmonology
• Inflammation

Context:

• Chronic obstructive pulmonary disease (COPD) is a complex respiratory condition with diverse clinical phenotypes.
• Current treatments for COPD often lack specificity for distinct disease subtypes.
• Roflumilast represents a novel therapeutic approach targeting specific inflammatory pathways in COPD.

Purpose:

• To review the clinical development of roflumilast, a phosphodiesterase-4 (PDE4) inhibitor.
• To evaluate roflumilast's efficacy and safety, particularly in COPD patients with chronic bronchitis.
• To assess roflumilast's utility in routine clinical practice settings.

Summary:

• Roflumilast is the first drug developed for a specific COPD phenotype: COPD associated with chronic bronchitis.
• Preclinical studies demonstrate potent anti-inflammatory actions relevant to COPD pathogenesis.
• Clinical evidence is reviewed, focusing on real-world applicability and therapeutic outcomes.

Impact:

• Roflumilast provides a targeted treatment option for a specific COPD phenotype, potentially improving patient management.
• This review synthesizes evidence supporting roflumilast's role in managing chronic bronchitis component of COPD.
• The findings contribute to understanding the clinical utility of PDE4 inhibitors in COPD therapy.